Bianca Hemmingsen1, Jeppe B Schroll2, Jørn Wetterslev1, Christian Gluud1, Allan Vaag3, David P Sonne4, Lars H Lundstrøm5, Thomas Almdal4. 1. Copenhagen Trial Unit, Centre for Clinical Intervention Research, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark. 2. Nordic Cochrane Centre, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark. 3. Department of Endocrinology, Copenhagen University Hospital, Copenhagen, Denmark. 4. Department of Internal Medicine, Copenhagen University Hospital Gentofte, University of Copenhagen, Hellerup, Denmark. 5. Department of Anaesthesiology, Nordsjællands Hospital, Hillerød, Denmark.
Abstract
BACKGROUND: Guidelines recommend metformin as the first-line oral treatment for type 2 diabetes. We conducted a systematic review to assess whether the use of second- and third-generation sulfonylurea agents is associated with benefits and harms in terms of patient-important outcomes compared with metformin. METHODS: We searched several electronic databases and other sources for randomized clinical trials published to August 2011. We included trials that compared sulfonylurea versus metformin monotherapy among patients 18 years or older with type 2 diabetes and that had an intervention period of at least 24 weeks. We assessed risk of bias and extracted data related to interventions and outcomes. The risk of random errors was assessed by trial sequential analysis. RESULTS: We included 14 trials (4560 participants). All trials were judged to be at high risk of bias. Data on patient-important outcomes were sparse. Compared with metformin, sulfonylurea did not significantly affect all-cause mortality (relative risk [RR] 0.98, 95% confidence interval [CI] 0.61 to 1.58) or cardiovascular mortality (RR 1.47, 95% CI 0.54 to 4.01). Sulfonylurea significantly decreased the risk of nonfatal macrovascular outcomes (RR 0.67, 95% CI 0.48 to 0.93). However, the definition of this outcome varied among trials, and trial sequential analysis showed that more trials are needed before reliable conclusions can be drawn. No differences between sulfonylurea and metformin were found for change in fasting blood glucose level or glycosylated hemoglobin concentration in the random-effects model. Sulfonylurea resulted in greater weight gain compared with metformin, a finding confirmed in the trial sequential analysis. Significantly more patients in the sulfonylurea arm than in the metformin arm had mild hypoglycemia (RR 2.95, 95% CI 2.13 to 4.07) and severe hypoglycemia (RR 5.64, 95% CI 1.22 to 26.00). INTERPRETATION: Some evidence suggests that, compared with metformin, second- and third-generation sulfonylureas may not affect all-cause or cardiovascular mortality but may decrease the risk of nonfatal macrovascular outcomes among patients with type 2 diabetes. They may also increase the risk of hypoglycemia. In general, the available data were too few and inconsistent to provide firm evidence concerning patient-important outcomes in relation to the benefits and harms of sulfonylurea versus metformin monotherapy.
BACKGROUND: Guidelines recommend metformin as the first-line oral treatment for type 2 diabetes. We conducted a systematic review to assess whether the use of second- and third-generation sulfonylurea agents is associated with benefits and harms in terms of patient-important outcomes compared with metformin. METHODS: We searched several electronic databases and other sources for randomized clinical trials published to August 2011. We included trials that compared sulfonylurea versus metformin monotherapy among patients 18 years or older with type 2 diabetes and that had an intervention period of at least 24 weeks. We assessed risk of bias and extracted data related to interventions and outcomes. The risk of random errors was assessed by trial sequential analysis. RESULTS: We included 14 trials (4560 participants). All trials were judged to be at high risk of bias. Data on patient-important outcomes were sparse. Compared with metformin, sulfonylurea did not significantly affect all-cause mortality (relative risk [RR] 0.98, 95% confidence interval [CI] 0.61 to 1.58) or cardiovascular mortality (RR 1.47, 95% CI 0.54 to 4.01). Sulfonylurea significantly decreased the risk of nonfatal macrovascular outcomes (RR 0.67, 95% CI 0.48 to 0.93). However, the definition of this outcome varied among trials, and trial sequential analysis showed that more trials are needed before reliable conclusions can be drawn. No differences between sulfonylurea and metformin were found for change in fasting blood glucose level or glycosylated hemoglobin concentration in the random-effects model. Sulfonylurea resulted in greater weight gain compared with metformin, a finding confirmed in the trial sequential analysis. Significantly more patients in the sulfonylurea arm than in the metformin arm had mild hypoglycemia (RR 2.95, 95% CI 2.13 to 4.07) and severe hypoglycemia (RR 5.64, 95% CI 1.22 to 26.00). INTERPRETATION: Some evidence suggests that, compared with metformin, second- and third-generation sulfonylureas may not affect all-cause or cardiovascular mortality but may decrease the risk of nonfatal macrovascular outcomes among patients with type 2 diabetes. They may also increase the risk of hypoglycemia. In general, the available data were too few and inconsistent to provide firm evidence concerning patient-important outcomes in relation to the benefits and harms of sulfonylurea versus metformin monotherapy.
Authors: Lesley Wood; Matthias Egger; Lise Lotte Gluud; Kenneth F Schulz; Peter Jüni; Douglas G Altman; Christian Gluud; Richard M Martin; Anthony J G Wood; Jonathan A C Sterne Journal: BMJ Date: 2008-03-03
Authors: Christianne L Roumie; Adriana M Hung; Robert A Greevy; Carlos G Grijalva; Xulei Liu; Harvey J Murff; Tom A Elasy; Marie R Griffin Journal: Ann Intern Med Date: 2012-11-06 Impact factor: 25.391
Authors: Kristian Thorlund; Georgina Imberger; Michael Walsh; Rong Chu; Christian Gluud; Jørn Wetterslev; Gordon Guyatt; Philip J Devereaux; Lehana Thabane Journal: PLoS One Date: 2011-10-18 Impact factor: 3.240
Authors: Ioanna Tzoulaki; Mariam Molokhia; Vasa Curcin; Mark P Little; Christopher J Millett; Anthea Ng; Robert I Hughes; Kamlesh Khunti; Martin R Wilkins; Azeem Majeed; Paul Elliott Journal: BMJ Date: 2009-12-03
Authors: Charles E Leonard; Colleen M Brensinger; Christina L Aquilante; Warren B Bilker; Denise M Boudreau; Rajat Deo; James H Flory; Joshua J Gagne; Margaret J Mangaali; Sean Hennessy Journal: Diabetes Care Date: 2018-02-02 Impact factor: 19.112
Authors: Jiandong Zhou; Guoming Zhang; Carlin Chang; Oscar Hou In Chou; Sharen Lee; Keith Sai Kit Leung; Wing Tak Wong; Tong Liu; Abraham Ka Chung Wai; Shuk Han Cheng; Qingpeng Zhang; Gary Tse Journal: Acta Diabetol Date: 2022-02-03 Impact factor: 4.280